Unlock stock picks and a broker-level newsfeed that powers Wall Street.

February 2025's ASX Penny Stocks With Growth Potential

In This Article:

The Australian stock market has faced a slight downturn, with the ASX200 down 0.36% amid concerns over new tariffs on aluminium and steel imposed by the Trump administration. Despite these challenges, certain sectors like Utilities and Health Care have shown resilience, highlighting opportunities for investors to explore undervalued segments of the market. Penny stocks, often representing smaller or newer companies, remain a relevant investment area; when backed by strong financials and fundamentals, they can offer growth potential at lower price points.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.77

A$141.28M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.57

A$66.88M

★★★★★★

EZZ Life Science Holdings (ASX:EZZ)

A$1.90

A$89.63M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.495

A$306.97M

★★★★★☆

MaxiPARTS (ASX:MXI)

A$1.92

A$106.21M

★★★★★★

Dusk Group (ASX:DSK)

A$1.065

A$66.32M

★★★★★★

Helloworld Travel (ASX:HLO)

A$2.04

A$332.15M

★★★★★★

SHAPE Australia (ASX:SHA)

A$3.00

A$248.73M

★★★★★★

IVE Group (ASX:IGL)

A$2.19

A$339.21M

★★★★☆☆

Vita Life Sciences (ASX:VLS)

A$1.90

A$105.71M

★★★★★★

Click here to see the full list of 1,031 stocks from our ASX Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Articore Group

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Articore Group Limited operates as an online marketplace for art and design products across Australia, the United States, the United Kingdom, and internationally, with a market cap of A$68.15 million.

Operations: The company generates revenue of A$492.99 million from its Redbubble and Teepublic marketplaces.

Market Cap: A$68.15M

Articore Group Limited, with a market cap of A$68.15 million, operates as an online marketplace generating A$492.99 million in revenue from its Redbubble and Teepublic platforms. Despite being debt-free and having a sufficient cash runway for over three years, the company remains unprofitable with increasing losses over the past five years at 20.5% annually. Its short-term assets do not cover short-term liabilities, reflecting potential liquidity challenges. The management team is experienced but the board is relatively new, which may impact strategic stability amid recent executive changes like Ben Heap's temporary leave from the board.

ASX:ATG Financial Position Analysis as at Feb 2025
ASX:ATG Financial Position Analysis as at Feb 2025

Imugene

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Imugene Limited is a clinical-stage immuno-oncology company based in Australia that focuses on developing immunotherapies to activate the immune system for treating and eradicating tumors, with a market cap of approximately A$275.93 million.